Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00594191
Recruitment Status : Completed
First Posted : January 15, 2008
Last Update Posted : January 15, 2008
Information provided by:
Hospital Clinic of Barcelona

Brief Summary:
The purpose of this study is to evaluate the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG), as a surrogate marker of prognosis, and its safety in patients with cirrhosis and portal hypertension.

Condition or disease Intervention/treatment Phase
Cirrhosis Portal Hypertension Drug: Simvastatin Drug: Placebo Phase 2

Detailed Description:
Statins exert beneficial vascular effects independently of cholesterol reduction by improving endothelial dysfunction. In cirrhosis sinusoidal endothelial dysfunction further increases intrahepatic resistance and portal pressure. Previous studies have shown that statins improve hepatic endothelial dysfunction in cirrhosis, suggesting that statins could be an effective therapy for portal hypertension (PHT). This randomized controlled trial evaluated the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG), as a surrogate marker of prognosis, and its safety in patients with cirrhosis and PHT.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase IV-II Randomized, Multicenter, Placebo-Controlled Double-Blind Clinical Trial Evaluating the Effects of Continuous Simvastatin Administration on Hepatic and Systemic Hemodynamics in Patients With Cirrhosis.
Study Start Date : March 2004
Actual Primary Completion Date : April 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Simvastatin

Arm Intervention/treatment
Placebo Comparator: A
Placebo treatment
Drug: Placebo
Placebo with the same characteristics of the drug and at the same dose

Experimental: B Drug: Simvastatin
20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met

Primary Outcome Measures :
  1. Changes in hepatic venous pressure gradient (HVPG) [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Changes in systemic hemodynamics [ Time Frame: 4 weeks ]
  2. Changes in liver function tests [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age between 18 and 75.
  2. Clinical, analytical, ultrasound or pathological criteria of cirrhosis.
  3. Severe sinusoidal portal hypertension (HVPG >12 mmHg)
  4. Signed informed consent

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Advanced liver disease defined as one of the following: Prothrombin rate <40%, Bilirubin >5 mg/dl, hepatic encephalopathy > grade I or Child-Pugh score >12).
  3. Portal vein thrombosis
  4. Multinodular hepatocellular carcinoma or single hepatocellular carcinoma > 5 cm.
  5. Heart, renal or respiratory failure
  6. Previous portal-systemic shunt
  7. Treatment with organic nitrates
  8. Hypersensitivity to HMG-CoA reductase inhibitors
  9. Previous treatment with HMG-CoA reductase inhibitors
  10. Treatment with calcium channel blockers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00594191

Hepatic Hemodynamic Laboratory. Liver Unit. Hospital Clinic.
Barcelona, Spain, 08036
Servicio de Gastroenterología, Hospital Ramón y Cajal
Madrid, Spain, 28871
Servicio de Gastroenterología, Hospital Universitario General Gregorio Marañón
Madrid, Spain
Sponsors and Collaborators
Hospital Clinic of Barcelona
Principal Investigator: Jaime Bosch, MD Hospital Clinic of Barcelona

Responsible Party: Jaime Bosch /Professor of Medicine, University of Barcelona Identifier: NCT00594191     History of Changes
Other Study ID Numbers: SIMV-HTP2003
AEM 03-0434
First Posted: January 15, 2008    Key Record Dates
Last Update Posted: January 15, 2008
Last Verified: January 2008

Keywords provided by Hospital Clinic of Barcelona:
HMG-CoA reductase inhibitors
Portal hypertension
Variceal bleeding

Additional relevant MeSH terms:
Liver Cirrhosis
Hypertension, Portal
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Liver Diseases
Digestive System Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors